New connections Between Japan and Europe

The MAGIA MedTech Alliance and FBRI build new connections Between Japan and Europe by signing a Joint collaboration agreement.

On Tuesday, March 22, 2022, MAGIA, the Medtech Alliance for Global InternationAlisation to market, announces it has joined forces with FBRI (Foundation for Biomedical Research and Innovation at Kobe, Japan) to offer new collaboration opportunities to MedTech SMEs.

There are the signatures! On behalf of Life Science Nord, Managing Director Dr. Hinrich Habeck (top row center) signed the Memorandum of Understanding during a ceremony via web conference.

MAGIA2Market follows the first phase of the MAGIA project and brings together four European leading MedTech clusters: Bioindustry Park Silvano Fumero / bioPmed (coordinator, Piedmont), BioWin (Wallonia), Life Science Nord (Northern Germany) and Lyonbiopole (Auvergne-Rhône-Alpes) joining forces to continue the successful European strategic Cluster Partnership on MedTech.

The overall objective of the Alliance is to build and reinforce strong networks in its targeted countries, USA, China and Japan, to provide SMEs the opportunity to meet with potential partners, laying the groundwork for potential cooperation, both in terms of business agreements but also co-development or research collaboration.

In that framework, MAGIA and FBRI (Foundation for Biomedical Research and Innovation at Kobe) are pleased to announce the establishment of a new strategic partnership strengthening relationship between Japan and Europe.

This new collaboration agreement between the MAGIA partners and FBRI foresees mutual benefit and opportunities in the field of MedTech. The Memorandum aims at:

  • Being a multilateral goodwill agreement.
  • Establishing a general framework of further specific agreements.
  • Fostering agreements and joint developments programs between the companies of the MAGIA partners and those of FBRI.
  • Building a solid and long-lasting relationship for the benefit of each one’s regional enterprises.
  • Sharing knowledge about each one’s market in term of landing processes, barriers and opportunities.

By signing this new agreement, MAGIA pursues its primary objective and opens new doors for its MedTech SMEs while building a solid foundation for collaboration with the Japanese ecosystem.

More News

Hans Kuhn hands over responsibilities to his successors Mariela Aranda (left) and Julianna Shibao (right).
Hans Kuhn hands over responsibilities to his successors Mariela Aranda (left) and Julianna Shibao (right). (Picture: altona Diagnostics)

New management at altona Diagnostics in Argentina and Brazil

After more than six years at the helm of the Argentine and Brazilian subsidiaries of altona Diagnostics based in Buenos ...

Read more …
To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)
To illustrate the type of environments in which gold nanoparticles can be used, the nanoparticles approach densely packed regions of proteins. (Image: Ferdinand Otto, UHH)

"Stealth Effect"

An experiment led by a team of DESY and Universität Hamburg scientists has discovered that gold nanoparticles can move through liquid ...

Read more …
Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …